From Surf Wiki (app.surf) — the open knowledge base

Prinomastat

Chemical compound

| elimination_half-life = 1–5 hours

Prinomastat (code name AG-3340) is a matrix metalloproteinase (MMP) inhibitor with specific selectivity for MMPs 2, 3, 9, 13, and 14. Investigations have been carried out to determine whether the inhibition of these MMPs is able to block tumour metastasis by preventing MMP degradation of the extracellular matrix proteins and angiogenesis. Prinomastat underwent a Phase III trial to investigate its effectiveness against non-small cell lung cancer (NSCLC), in combination with gemcitabine chemotherapy. However, it was discovered that Prinomastat did not improve the outcome of chemotherapy in advanced non-small-cell lung cancer.

References

(February 2005). "Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer". Journal of Clinical Oncology.
(February 2004). "Phase I and pharmacokinetic study of prinomastat, a matrix metalloprotease inhibitor". Clinical Cancer Research.

Info: Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

experimental-cancer-drugs hydroxamic-acids matrix-metalloproteinase-inhibitors sulfonamides 4-pyridyl-compounds

Want to explore this topic further?

Ask Mako anything about Prinomastat — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report